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The prognostic utility of the transcription
factor SRF in docetaxel-resistant prostate
cancer: in-vitro discovery and in-vivo
validation
D. J. Lundon1*, A. Boland3, M. Prencipe1, G. Hurley2, A O’Neill1, E. Kay5, S. T. Aherne4, P. Doolan4, S. F. Madden2,
M. Clynes4, C. Morrissey6, J. M. Fitzpatrick1 and R. W. Watson1
Abstract
Background: Docetaxel based therapy is one of the first line chemotherapeutic agents for the treatment of
metastatic castrate-resistant prostate cancer. However, one of the major obstacles in the treatment of these patients
is docetaxel-resistance. Defining the mechanisms of resistance so as to inform subsequent treatment options and
combinations represents a challenge for clinicians and scientists.
Previous work by our group has shown complex changes in pro and anti-apoptotic proteins in the development of
resistance to docetaxel. Targeting these changes individually does not significantly impact on the resistant
phenotype but understanding the central signalling pathways and transcription factors (TFs) which control these
could represent a more appropriate therapeutic targeting approach.
Methods: Using a number of docetaxel-resistant sublines of PC-3 cells, we have undertaken a transcriptomic
analysis by expression microarray using the Affymetrix Human Gene 1.0 ST Array and in conjunction with
bioinformatic analyses undertook to predict dysregulated TFs in docetaxel resistant prostate cancer. The clinical
significance of this prediction was ascertained by performing immunohistochemical (IHC) analysis of an identified
TF (SRF) in the metastatic sites from men who died of advanced CRPC. Investigation of the functional role of SRF
was examined by manipulating SRF using SiRNA in a docetaxel-resistant PC-3 cell line model.
Results: The transcription factors identified include serum response factor (SRF), nuclear factor kappa-B (NFκB), heat
shock factor protein 1 (HSF1), testicular receptor 2 & 4 (TR2 &4), vitamin-D and retinoid x receptor (VDR-RXR) and
oestrogen-receptor 1 (ESR1), which are predicted to be responsible for the differential gene expression observed in
docetaxel-resistance. IHC analysis to quantify nuclear expression of the identified TF SRF correlates with both
survival from date of bone metastasis (p = 0.003), survival from androgen independence (p = 0.00002), and overall
survival from prostate cancer (p = 0.0044). Functional knockdown of SRF by siRNA demonstrated a reversal of
apoptotic resistance to docetaxel treatment in the docetaxel-resistant PC-3 cell line model.
Conclusions: Our results suggest that SRF could aid in treatment stratification of prostate cancer, and may also
represent a therapeutic target in the treatment of men afflicted with advanced prostate cancer.
Keywords: Prostate Cancer, Adenocarcinoma of prostate, Metastatic prostate cancer, Androgen-independent
prostatic cancer, Docetaxel resistance, Anti-neoplastic agent resistance, Drug resistance, Personalised medicine,
Translational oncology
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Background
Prostate cancer is the second most common cause of
cancer and the sixth leading cause of cancer death
amongst men worldwide [1]. Approximately 15% of men
diagnosed with prostate cancer will die because of
advanced metastatic disease; the majority of whom have
castration resistant disease; and many of these will have
received one or more treatment options [2]. Publications
by Tannock et al. and Petrylak et al. demonstrated that
docetaxel improved survival for men with metastatic
castration resistant prostate cancer (mCRPC) [3, 4].
Despite new treatment options for prostate cancer,
advanced disease still represents a challenge for treat-
ment, and current treatment options for castration
resistant disease offer limited survival advantage due to
the development of resistance [5, 6].
Resistance to docetaxel is poorly understood, and may
be caused by a number of mechanisms. These mecha-
nisms include: (1) the fact that prostate tumours are
slow-growing and are unlikely to respond to drugs that
are S-phase dependent [7]. However, recent clinical trial
data combining hormone ablation and docetaxel in
hormone and chemo-naïve patients demonstrated an
18 month median overall survival (OS) advantage in
patients with high volume prostate cancer [8]. (2)
Reduced intra cellular concentrations of cytotoxic drugs
as a result of alterations in drug transporters, particularly
P-glycoprotein [9, 10]. (3) Tumour suppressor protein
mutations, such as the loss of PTEN results in increased
cellular proliferation and survival as well as activation of
the phosphatidylinositol 3′-kinase (PI3K) signal transduc-
tion cascade [10, 11]. This is mediated through altered
expression of survival factors that inhibit the apoptotic cell
death pathway [10], mediated in part by survival signalling
pathways such as the activation of AKT. (4) Alterations in
β-tublin isotypes which exhibit different kinetics of micro-
tubule formation particularly isotypes III and IV correlate
with docetaxel resistance in vitro [12]. However the identi-
fication and manipulation of these multiple mechanisms
of resistance represents a significant challenge and target-
ing individual proteins may have little clinical impact.
More recently, O’Neill et al. undertook to characterise
docetaxel resistance in prostate cancer cell lines [10]. This
study highlighted a complex interplay between changes in
the expression of both pro- and anti-apoptotic proteins
which ultimately contributed to docetaxel resistance.
In the context of advanced, metastatic castration and
docetaxel resistant prostate cancer, one or many of these
pathways may be involved in its development. We
hypothesised that by understanding the central signalling
pathways and transcription factors (TFs) which govern
multiple downstream genes we could identify key tran-
scription factors, that when manipulated would alter
docetaxel resistance. This study was undertaken to
expand our understanding of the mechanisms of resistance
to Docetaxel using our previously described PC-3 doce-
taxel resistant model [10].
Our objectives were to identify TFs which could
account for this resistant phenotype in a model of doce-
taxel resistance, to validate these TFs in tissue from men
who have died from docetaxel resistant mCRPC, and to
evaluate if functional manipulation of such TFs could
alter response to docetaxel therapy.
Methods
Cell lines
The human prostate cancer cell lines PC-3 were pur-
chased from the American Type Culture Collection
(ATCC CRL-1435). PC-3 resistant sublines (D8, and
D12) and their corresponding age matched controls (Ag)
were generated and maintained as previously described
[10]. Briefly, these resistant sub-lines were generated by
initially treating cells with increasing doses of docetaxel
starting at 4 and 8nM respectively, escalating to 8 and
12 nm respectively with recovery periods between treat-
ments of 2–3 weeks and treatments cycled over a period
of 6 months. Their characteristics and IC50 have been
previously published [10].
RNA preparation and microarray analysis
Total RNA was isolated from the three PC-3 cell lines
(aged matched control [Ag] and the 2 resistant sublines
[D8, D12]) in four replicates; using methods previously
described [6]. The Affymetrix Human Gene 1.0 ST Array
containing 764,885 probe sets was used to perform gene
expression profiling, and was used in accordance with
the manufacturer’s instructions.
Gene expression values were calculated using the
robust multichip average method [13] and data were
quantile normalized using the Bioconductor package affy
[14]. Differential gene expression lists were generated
using the ebayes function of the limma package from
Bioconductor [15]. The P-values were adjusted for mul-
tiple testing using the Benjamini and Hochberg method
[16]. An adjusted P-value of <0.01 was considered
significant. The choices of comparisons within the data-
sets were guided by the unsupervised co-inertia analysis
(CIA) that is parental versus D8 and parental versus
D12. The final gene list was determined by consistent
overlap between these two comparisons.
Co-Inertia Analysis (CIA)
The microarrays were analysed using a method for inte-
grating gene expression data with known and predicted
transcription factor binding site (TFBS) information
[17]. This method uses CIA [13, 18] to combine two
linked datasets, performing two simultaneous non-
symmetric correspondence analyses and identifying the
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axes that are maximally co-variant. CIA is first applied
in an unsupervised manner and then rerun in a super-
vised manner using between group analysis (BGA). This
analysis was performed as previously described [6].
The final TF list was determined by overlap between
these two ranked lists. All calculations were carried out
using the MADE4 library [19] of the open source R
package (http:// www.bioconductor.org).
Transcription factor binding site information
The TFBS information, which is integrated with the gene
expression data using CIA has been previously published
[17]. It contains the TFBS information for 1,236 known
and predicted TFBS conserved across human, mouse, rat
and dog in the promoters of approximately 17,000 genes.
This information was generated at four different position
specific scoring matrix thresholds, 0.7, 0.75, 0.8, and
0.85 giving four gene/TFBS frequency tables. In the
supervised CIA these thresholds are combined using the
Rank Products method [20], giving a ranked list of TFs
associated with docetaxel-resistance.
Total cellular protein isolation and western blot analysis
Whole cell lysates were extracted from treated cells
grown to 90% confluence on T75 flasks and 6-well plates
as previously described [10]: Cells were washed in cold
PBS (1100 rpm, 1 min, 4 °C in a microcentrifuge) and
then re-suspended in Tris 10 mM, 60 mM KCl, NP-40,
1 mM EDTA, 1.0 mM DTT, 10 μl/ml Protease Inhibitor
Cocktail (Sigma P8340)/1 ml of lysis buffer and 10 mM
PMSF. Samples were then placed on ice for 10 mins and
the cell lysate collected after centrifugation (13000 rpm
5 mins at 4 °C).
Total cellular protein was determined by means of the
Bradford Assay Protein Detection Kit (Bio-Rad) as previ-
ously described [10]. Equal amounts of protein (50 μg)
were subjected to SDS polyacrylamide gel electrophor-
esis on 8–12% gels before being trans-blotted onto
Immobilin P (Millipore) membranes as previously pub-
lished [10]. The following primary antibodies were used:
anti-SRF (1:1,000, Santa Cruz) and ß-actin (1:5,000,
Sigma–Aldrich). Densitometry values were calculated
using ImageJ software [21].
Small-Interfering RNA (siRNA) transfection
PC-3 parental and D12 cells were seeded in 6-well
plates at a density of 250,000 cells per well. Twenty
four hours later, cells were transfected with siGEN-
OME SMART pool targeting serum response factor
(SRF) (Dharmacon siGenome Human SRF #6722) or
siControl siRNA (Dharmacon), at a final concentra-
tion of 20 nM, using Lipofectamine 2000 (Invitrogen).
This commercially prepared product utilises a proprietary
algorithm (SMARTselection algorithm™) to pool 5 SRF
siRNA to alleviate off target effects and maintain effective
silencing of SRF.
Flow cytometric analysis of apoptosis
Apoptotic events were described as a percentage of
total events with hypo-diploid DNA assessed by pro-
pidium iodide incorporation as previously described
[10, 22]. Briefly, cells were harvested by trypsinisation,
permeabilised with a hypotonic fluorochrome solution
(50 mg/ml PI, 1 mM Tris, 0.1 mM EDTA, 3.4 mM
sodium citrate and0.1% TritonX-100) and incubated
for 10 min prior to analysis. Samples were run on a
Beckman-Coulter FC-500 Cytometer. Ten thousand
events were gated on PI intensity and analysed using
CXP software (Beckman-Coulter).
3-(4,5)-dimethylthiazol-2-yl-2,5-diphenyltetrazolium
bromide (MTT) assay cell viability assay
Cell viability was assessed by MTT cell staining as previ-
ously described [23]. Briefly, MTT (50 μl of a 5 mg/ml
in PBS; Sigma-Aldrich) was added to each well and the
cells were incubated in a CO2 incubator at 37 °C for 5 h.
Following media removal, the MTT-formazan formed by
metabolically viable cells was dissolved in 200 μl of
DMSO (Sigma- Aldrich) and the absorbance was mea-
sured in a plate reader at 550 nm.
Sample collection/tissue microarray construction
Human tissue microarrays were constructed consisting
of 65 soft tissue metastases and 120 bone metastases
from 42 patients with advanced prostate cancer as previ-
ously described [24]. This cohort had been recruited and
work performed prior to the advent of novel anti-
androgens (such as enzalutamide and abiraterone), how-
ever 50% of the cohort received radiotherapy and over
95% had received various combinations of therapies
(chemotherapeutic agents/ immunotherapies). Samples
were obtained from patients who died of mCRPC and
who signed written informed consent for a rapid autopsy
to be performed ideally within 2 h of death, under the
aegis of the Prostate Cancer Donor Program at the
University of Washington [24]. Cohort characteristics
are outlined in Additional file 1: Table S1. Two replicate
1 mm cores of soft tissue metastases and bone metasta-
ses were taken from every patient where available [25].
The tissue microarrays were assembled using the Beecher
Instruments Tissue-Arrayer™ (Beecher Instruments, Silver
Spring, MD).
Immunohistochemical (IHC) analysis
Immunohistochemical staining for SRF was performed
using a microwave-induced antigen retrieval method as
previously described [26]. De-waxed sections were
immersed in a citric acid buffer and placed in a 700 W
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microwave oven at full power for 15 min. Using a stand-
ard avidin-biotin complex method (Vector Laboratories,
Inc.), the sections were incubated with polyclonal rabbit
(Santa Cruz Biotechnology, Inc. – 1:800 dilution) at 4 °C
overnight. The colour reaction product was obtained
with DAB and counterstained with Haematoxylin. Tonsil
sections were used as positive controls. Prior to this
study, the SRF antibody was subjected to western blot
analysis using LNCaP and PC-3 prostate cancer cell lines
which confirmed specificity for SRF [6].
Scoring of SRF protein expression and statistical analysis
Nuclear immunoreactivity for SRF was assessed in soft
tissue metastases and bone metastases by two independ-
ent observers (GOH) (EK). Unusable cores were found
in the TMAs due to the tissue cores being missing, can-
cer necrosis, or insufficient cancer cells. These cores
were excluded from the study. The cohort was divided
using quartiles based on survival: [a] from diagnosis with
prostate cancer [b] from diagnosis with CRPC and [c]
from diagnosis with first bone metastasis; with the aim
of extracting relatively homogenous subsections from an
otherwise heterogeneous group. For the purpose of
statistical analysis, immune-expression of the protein
was graded according to the following scales: 0, no stain-
ing, 1, faint but clearly detectable staining in >10% of
epithelial cells, 2, moderate staining in >10% of epithelial
cells and 3, strong staining in >10% of epithelial cells.
The staining intensity of SRF in the nuclei of epithelial
cells was then further divided into two groups: low expres-
sion (immunohistochemical score of 0 or 1) included
those with negative or weak staining and high expression
(immunohistochemical score of 2 or 3) included those
with moderate or strong reactivity. Each individual’s SRF
positivity was calculated by obtaining an average score of
their sites of [i] bone metastasis, [ii] soft tissue metastasis
[iii] both bone and soft tissue metastasis.
Chi square tests and Fisher exact tests were performed
on 2X2 contingency tables using IBM SPSS 20 for
Windows® to test the association of SRF immunohisto-
chemical score (positive (2/3) and (negative (0/1)) with
CRPC metastases type (bone metastases versus soft
tissue metastases). Spearman’s rank correlation was per-
formed using continuous variables, Kaplan-Meier curves
plotted and logrank test performed using IBM SPSS 20
for Windows to test the relationship between SRF im-
munohistochemical score versus survival time from
[a] diagnosis with PCa, [b] diagnosis with CRPC and
[c] diagnosis with first bone metastasis. Multivariate
analyses including other relevant clinical and patho-
logical data available (age, primary and secondary
Gleason score, number of bone metastases, number
of soft tissue metastases, total number of metastases)
was performed.
Results
Supervised CIA and differential gene expression analysis
of PC-3 Cell line model of docetaxel resistance identifies
TFs associated with docetaxel resistance
To identify mechanisms of resistance to docetaxel within
our dataset, all microarray data was analysed using CIA
to integrate mRNA gene expression data and TFBS
information in the promoters of the same genes. CIA
was first applied in an unsupervised manner to the 12
arrays (four replicates for each cell line) and the associ-
ated TFBS/gene frequency tables to identify underlying
trends in the data in each cell line. The aim of this
analysis was to identify the TFs responsible for such
trends and the differentially regulated genes they were
predicted to target. An unsupervised CIA at the 0.85
PSSM thresholds (Fig. 1) was used for data exploration
purposes. There was separation between the PC-3
parental cell line (Ag) and the docetaxel resistant subline
(D8) along the vertical axis and between D12 and both
the PC-3 parental cell line (Ag) and docetaxel resistant
subline (D8) along the horizontal axis (Fig. 1a) and simi-
larly for the transcription factor binding site (TFBS) motifs
in the respective cell lines (Fig. 1b). These observations
guided our choice of comparisons for both the supervised
CIA and the differential gene expression analysis: Ag
versus D8 versus D12.
To identify the TFBS specifically associated with
docetaxel-resistance, we performed a supervised analysis
of the data combining CIA and BGA using a methodology
previously described [6]. This analysis returned three lists
Fig. 1 Unsupervised CIA of the PC-3 cell lines. A gene/transcription
factor binding site (TFBS) frequency table produced with a position-
specific scoring matrix (PSSM) threshold of 0.85 was used. a: The
projection of the samples shows a clear separation between the
parental and the two docetaxel resistant cell lines. b: The projection
of the TFBS motifs is shown. Motifs that are in the same orientation
as the docetaxel resistant cell lines in Fig. 1a are associated
with docetaxel-resistance
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of motifs that were ranked based on the motif ’s associ-
ation with the docetaxel resistant cell lines. These lists of
TFBS were then combined using the Rank Products
method. Supervised CIA was used to analyse Ag versus
D8, and Ag versus D12. The TFBS associated with doce-
taxel resistance were based on the overlap between these
two comparisons.
The binary comparison between parental and D8 and
parental and D12 were overlapped to identify genes
which were differentially regulated in both cell lines.
There were 716 probes up-regulated and 986 probes
down-regulated between the two comparisons, indicat-
ing a tightly controlled experiment, and which corre-
sponded to 301 distinct genes. Those genes, which were
taken for further pathway analysis are listed in Additional
file 2: Table S2, and the TFs that are predicted to target
them are listed in Table 1. Close interplay between a sub-
network of some of these TFs was identified and SRF was
selected for further investigation.
SRF expression is negatively correlated with docetaxel-
resistance in metastatic castration resistant prostate
cancer bone metastases
To evaluate SRF expression in mCRPC, we scored
IHC staining of metastatic sites from 42 patients who
died of CRPC. From this cohort, those who were
treated with docetaxel were identified: 23 patients and
83 metastatic sites.
Among 83 metastatic sites, 29 (35%) sites displayed
positive nuclear SRF expression and 54 (65%) sites
displayed negative SRF nuclear expression (see Fig. 2).
The metastatic samples were then further divided into
bone metastases versus soft tissue metastases. Out of a
total of 52 bone metastatic sites, 20 (38%) sites had posi-
tive SRF nuclear expression and 32 (62%) sites displayed
negative SRF nuclear expression. Out of a total of 31 soft
tissue metastatic sites, 9 (29%) sites had positive SRF nu-
clear expression and 22 (71%) sites displayed negative SRF
nuclear expression. Stepwise regression was performed
including available clinical and pathological data were
significant in the model.
SRF expression in docetaxel resistant prostate cancer
correlates with survival
A negative correlation was identified between SRF nuclear
expression in bone metastases and survival from date of
diagnosis with prostate cancer (Fig. 3a[i]; Spearman Rank
Correlation −0.602, median difference in survival was
5.68 years), castration resistance (Fig. 3b[i]; Spearman
Rank Correlation −0.813, median difference in survival
was 2.89 years), and bone metastases (Fig. 3c[i]; Spearman
Rank Correlation −0.672, median difference in survival
was 3.6 years). Kaplan-Meier analysis was performed
which confirmed SRF negative correlation from date
of diagnosis with prostate cancer (Fig. 3a[ii]; Log-rank
test, P = 0.003), castration resistance/ biochemical re-
currence (Fig. 3b[ii]; Log-rank test, P = 0.00002), and
bone metastases (Fig. 3C[ii]; Log-rank test, P =
0.0044). No association between SRF nuclear expres-
sion in soft tissue metastases and duration to death
from diagnosis with prostate cancer (P = 0.744), diag-
nosis with CRPC (P = 0.292) or diagnosis with bone
metastasis (P = 0.312) was observed.
In the portion of this cohort that did not receive doce-
taxel, median survival times from diagnosis with prostate
cancer, castration resistance and bone metastasis were
4.95 years, 1.09 years and 2.22 years respectively, none
of which were significantly different from the survival
times in the docetaxel resistant cohort whose survival
times from these time points were 5.33, 3.16 and 2.09 years
respectively; (the respective p-values are 0.36, 0.26 and 0.28,
denoting no significant difference in survival times between
the docetaxel-resistant and docetaxel-naïve sub-cohorts).
When these sub-cohorts are further sub-divided by
their expressivity of SRF in bone metastases (high SRF
expressivity vs low SRF expressivity), as described above
low SRF correlates with longer survival times from diag-
nosis, castration resistance and bone metastasis in the
Table 1 List of predicted transcription factors (TFs) associated with docetaxel-resistance
Symbol of predicted target Description RefSeq Accession Log (Fold Change) P-Value
NFKB2 Nuclear factor of Kapa Light Polypeptide gene enhancer in B-cells 2 NM 002502 −0.769367 0.000829
SRF c-fos serum response element-binding transcription factor NM_003131 0.830936 0.000984
TR2 nuclear receptor subfamily 2, group C, member 1 NM_003297.3 0.93892 0.000149
TR4 nuclear receptor subfamily 2, group C, member 2 NM_003298.3 −2.117639 1.54E-05
NR1H2 nuclear receptor subfamily 1, group H, member 2 NM_007121 2.086756 1.36E-05
BRN5 POU domain, class 6, transcription factor 1 NM_002702.3 1.090898 0.011998
PPAR_RXR peroxisome proliferator-activated receptor alpha NM_001001928.2 −0.570508 0.025654
ER estrogen receptor 1 NM_000125.3 1.7681357 8.57E-06
NFE2L2 nuclear factor (erythroid-derived 2)-like 2 NM_001145412.2 0.415401 0.010718
Transcriptomic data was integrated with known and predicted transcription factor binding sites (TFBS) resulting in a list of transcription factors (TFs) associated
with the differential gene expression observed with the transcriptomic profiling
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context of docetaxel resistance; however in the context
of docetaxel naïve patients, SRF level does not correlate
with survival times from these three clinically relevant
time points (p values = 0.29, 0.30 and 0.38 respectively).
Functional relevance of SRF in a docetaxel resistant
model of advanced prostate cancer
Docetaxel treatment increases SRF transcriptional activity in
docetaxel-resistant model
To evaluate the functional role of SRF in the PC-3 model
of docetaxel-resistance, we assessed transcriptional activity
of SRF at baseline and following 48 h of treatment with do-
cetaxel, in both a docetaxel-resistant subline (D12) and
aged matched controls (Ag) (Fig. 3), using a dual-luciferase
assay system. PC3-Ag cells demonstrated significantly
greater SRF transcriptional activity than PC3-D12 cells at
baseline. Following treatment with docetaxel, there was no
increase in the relative SRF transcriptional activity in the
PC3-Ag cells, but a greater than 2× increase in SRF tran-
scriptional activity in the PC3-D12 cells (p = 0.009) (Fig. 4).
This observation that SRF transcriptional activity is
increased in response to docetaxel treatment in these
resistant cells, but not in the docetaxel sensitive cells
suggests that SRF transcriptional activation is a survival
pathway in docetaxel resistance.
SRF knockdown (siRNA) re-sensitises resistant cells to
docetaxel
To investigate if manipulation of SRF transcriptional
activity in the resistant subline (PC3-D12) alters the sen-
sitivity of these cells to docetaxel, 20nM SRF siRNA
transfection was performed and cells allowed to recover
for 48 h. Knockdown of SRF was confirmed at the pro-
tein level (Fig. 5a). Following knockdown, cells were
treated with docetaxel [20nM] for 48 h. Cells were then
assessed for apoptosis and viability. Flow cytometric ana-
lysis demonstrated no change in apoptosis in PC3-Ag
cells but a significant increase in apoptosis in the PC3-
D12 cells post-docetaxel treatment (P < 0.01) (Fig. 5b).
Cell viability assessed by MTT assay similarly demon-
strated no change in viability in the PC3-Ag whilst
PC3-D12 cells demonstrated a significant reduction in
viability (p < 0.01) (Fig. 5c).
Discussion
Gene expression profiling has been shown to predict
clinical outcomes of prostate cancer [27] but complex
gene expression profiles are often difficult to manipulate.
Targeting the TFs associated with this profile may
represent a better therapeutic approach. This study pre-
dicted TFs associated with docetaxel-resistance based
Fig. 2 Representative images of serum response factor (SRF) protein expression assessed by immunohistochemistry on docetaxel resistant
prostate cancer metastases; low power magnification of entire core and 40× magnification inset. Clockwise from top left a: bone metastasis
demonstrating strong nuclear SRF expression, b: Bone metastasis demonstrating weak SRF nuclear expression, d: Soft tissue metastasis
demonstrating weak SRF nuclear expression, c: Soft tissue metastasis demonstrating strong nuclear SRF expression. Images magnified × 40
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on transcriptomic data by utilising an innovative bio-
informatics approach (CIA) and compared gene expres-
sion profiling of the PC3- Ag cells versus the docetaxel
resistant cell lines D8 and D12. In line with recent tran-
scriptomic studies by our group and others on
castration-resistance [6, 28–31], analysis of our gene
chip data showed gene expression changes in cellular
processes relevant to cancer progression. These in-
cluded cell proliferation, apoptosis, cell growth, survival
and senescence and cell death with 375 unique genes
differentially expressed between the parental Ag and
docetaxel resistant sublines D8 and D12. The focus on
upstream TFs regulating the transcriptomic profile
rather than the gene expression offered the most novel
insights: where transcriptomic data of docetaxel resist-
ant cell lines was combined with a database of TFBS to
identify TFs associated with docetaxel-resistance. The
utilisation of this approach generated a list of 9 TFs
(Table 1) predicted to be associated with docetaxel
resistance in prostate cancer. Members of this list have
previously been associated with prostate cancer, where
decreased expression of ESR1 has been found to be
particularly associated with hormone refractory dis-
ease [32], and PPARγ whose activity is regulated by
direct binding of steroid and thyroid hormones,
vitamins, lipid metabolites and xenobiotics and have
been shown to participate in the development of the
disease [33, 34].
Novel factors associated with docetaxel resistance in
prostate cancer included: (1) SRF which is known to be
involved with cancer development and progression and
its role in castration resistance was previously outlined
by our group [6]. (2) BRN5, a pou domain TF of which
very little is known, and (3) TR2 and TR4; members of
the orphan nuclear receptor family, for which activation
or deactivation involves an intricate interplay of different
structural classes of endogenous ligands such as the
heterodimeric receptors that partner with the retinoid X
receptor and bind retinoids and vitamin D [35]. In
support of our findings, in recent months Chen et al.
Fig. 3 Correlation of SRF expression in bone metastases and survival: Tissues of docetaxel resistant prostate cancer bone metastases obtained at Rapid
Autopsy were stained for SRF (N = 23). Time from (a) Prostate Cancer Diagnosis, (b) Castration Resistance and (c) Bone Metastases to death [Survival
(Years)] was correlated with positivity of SRF in stained tissue samples. Correlation curves (i) and Kaplan-Meier curves (ii) at each of these time points
respectively demonstrate the strong statistically significant negative correlation between nuclear expressivity of SRF and survival outcomes
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demonstrated that TR4 enhances the chemo-resistance
of docetaxel in CRPC, and that it may serve as a bio-
marker to determine the prognosis of docetaxel-based
therapy [36].
The dataset and TF list identified by our study repre-
sents a useful resource for future studies on docetaxel-
resistance with valuable targets to be explored, as resist-
ance is complex and the mechanisms underlying it
multifarious [37]. For the purpose of validating this
study we chose to further investigate the functional
significance of SRF. SRF is expressed in mature soft
tissues such as lung, liver and prostate and has been
noted to be dysregulated in a number of malignant
tissues such as prostate, breast, gastric and liver carcin-
oma [38–44]. In primary gastric cancers- high SRF
correlates with a more invasive cancer phenotype and
high SRF acts as an independent risk factor of short
disease free survival [38]. SRF has been associated with
prostate cancer development and progression [45–48],
and our group have previously studied its role in the
development of castration resistance [49]. SRF has also
recently been associated with androgen receptor (AR)
hypersensitivity; where a negative feedback loop exists
between SRF expression and AR transcriptional activity
in the setting of castrate-resistant prostate cancer [50].
This study gave us the opportunity to expand our
understanding of SRF’s role in docetaxel resistance, in
the context of AR negative and docetaxel resistant PC-3
cells, and clinical tissues from castrate and docetaxel
resistant prostate cancer.
The treatment of men with mCRPC has seen a large
number of changes since 2004. Prior to 2004, men who
failed primary androgen deprivation were then treated
palliatively. Since 2010 the therapeutic armamentarium
has increased, but median survival of mCRPC in the
post-docetaxel setting is 15-18months [51, 52]. This has
led to calls for biomarkers of treatment response and a
deeper understanding of the tumour heterogeneity and
molecular biology underlying the disease [5]. Previous
studies have demonstrated that SRF is associated with
Gleason grade and extracapsular extension [46], poor
post-operative outcome [45], and castration resistance
[6]. To our knowledge, this study is the first to charac-
terise the role of SRF in docetaxel-castration resistant
prostate cancer. We found that nuclear tissue expression
of SRF is significantly dysregulated in bone metastases of
men with mCRPC in the post-docetaxel setting; such
that low SRF expression is associated with significantly
longer time to bone metastasis. Our research group and
others have previously reported that SRF nuclear positivity
is associated with higher Gleason score in primary pros-
tate cancer tissues [46] and castrate-resistant TURPs [6]
Fig. 4 SRF transcriptional activity was assessed in Ag and PC3 docetaxel resistant (D12) cells which were seeded in 12-well plates at a density of
100,000 cells per well. The following day they were transiently transfected using a dual luciferase assay system, where the reporter construct is
driven by SRF and tK renilla responsive elements. Twenty-four hours post-transfection, cells were treated with either 20 nM docetaxel or a similar
volume of vehicle control for 6 h. Reporter gene activity was then measured by illuminometry, and relative SRF:tkRenilla transcriptional activity
calculated. * = p < 0.05. No statistical difference between SRF transcriptional activity in PC3-Ag cells at baseline vs. treatment with docetaxel was
observed (represented by the dashed line). (n = 3.)
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suggesting that SRF may play a role in prostate cancer
progression. Additionally our group has demonstrated an
association between SRF nuclear positivity and castration-
resistant TURPs, with 95% of castrate-resistant TURPs
showing nuclear positivity for SRF [6]. In our study of
prostate cancer metastases to bone and soft tissue in men
with advanced disease, approximately 40% displayed SRF
nuclear positivity. In this cohort of men with mCDRPC, a
negative association between SRF nuclear expression in
bone metastases and survival from time of diagnosis with
(1) prostate cancer (2) diagnosis with CRPC and (3) diagno-
sis with first bone metastasis was seen, which was inde-
pendent from the number of metastatic sites. No significant
association was noted between SRF and survival times in
those men with mCRPC who had not been treated with
Docetaxel. This finding demonstrates that with disease
progression from localised prostate cancer, castration
resistance and bone metastases; patients’ survival was
inversely correlated with nuclear SRF expression in the
context of docetaxel resistance.
Our group has also recently demonstrated that SRF
has a negative association with the androgen receptor in
CRPC and SRF is involved in the development of castra-
tion resistance [50]. In this cohort of men with mCRPC,
the median difference in duration of androgen ablation
between those subsequently classified as “high SRF and
“low SRF” was 4.3 years (p = 0.000019). These findings
suggest that those who have higher SRF are likely to
have had more aggressive/adaptive disease, having evolved
resistance to castration significantly sooner (by 4.3 years).
Fig. 5 Functional Manipulation of SRF. a PC3-Age matched control (Ag) and PC3-docetaxel resistant (D12) cells for Western blotting analysis of
SRF. β-actin was used as loading control. Fifty microgrammes of protein from untreated control (Ctrl), cells transfected with an empty vector;
scramble control (Sc) and cells transfected with SRF siRNA knockdown (siRNA), were loaded into their respective wells. A representative image
from three independent experiments is shown. SRF knockdown by siRNA was performed 48 h prior to treatment with 20 nM docetaxel for a
further 48 h in 6 well plates seeded with ~100,000 cells per well of Ag and D12 cell lines respectively. b: Apoptosis was assessed using propidium
iodide and flow cytometry (n = 3) and (c) Viability was assessed by MTT assay (n = 3). * = p < 0.05. ** = p < 0.01
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Our data demonstrates a non-significant trend amongst
those with SRF and duration of docetaxel therapy; with
those with high SRF having received docetaxel for a
shorter duration (median 0.166 years) compared to those
with a low SRF (median duration 1.05 years).
This transition of SRF expression levels from primary
to metastatic tissues, castration resistance and docetaxel
therapy, amongst other factors, may explain the findings
of a phase III randomised controlled trial. CHAARTED
randomized men with newly diagnosed metastatic pros-
tate cancer to ADT alone or ADT plus 6 cycles of doce-
taxel [8]. In this castration sensitive group, Sweeney et
al. described a median OS of 57.6 months in the ADT
plus docetaxel group, versus 44 months median OS in
the ADT alone group (p = 0.003). This survival benefit
contrasts sharply with docetaxel therapy in the castra-
tion resistant setting where median survival was
18.9 months in the docetaxel q 3 weekly group, versus
16.5 months median overall survival in the mitoxan-
throne group (p = 0.009) [4]. Nuclear SRF expression is
associated with castration resistance [6], and nuclear
positivity is associated with shorter survival from castra-
tion resistance [26], and this study has demonstrated
that high SRF expression after docetaxel therapy is
correlated with a shorter survival. SRF and other factors
likely represent a marker of disease progression; a com-
mon denominator or a waypoint in the pathway through
which docetaxel and androgen ablation therapies exert
their therapeutic effect in prostate cancer (so that men
receiving combination therapy in CHAARTED who have
progressive disease, are likely to express high levels of
SRF in their primary tumour and bone metastases.
The finding that nuclear expression of SRF in soft
tissue metastases does not correlate with survival from
diagnosis with prostate cancer, castration resistance or
first bone metastasis is likely due to a combination of
factors including the heterogeneity of prostate cancer
metastases, features unique to the respective microenvi-
ronments as opposed to just differential bioavailability of
docetaxel in various tissue types. This distinction of
microenvironmental factors from bioavailability in bone
is made as Brubaker et al. have shown in in-vivo models
of prostate cancer that docetaxel at a dose which effect-
ively inhibits growth of subcutaneous tumours did not
show any effect on the tumours in bone [53]. Meanwhile,
Van Der Veldt et al. demonstrated adequate bioavailability
of docetaxel in vertebrae in cancer patients, which was
comparable to the bioavailability of docetaxel in lung
tissues of these patients [54]. This differential effect of
docetaxel in different tissue types, may in part be ex-
plained by SRF; SRF is associated with mesodermal forma-
tion; the embryonic germ layer from which bone and
skeletal muscle is derived, in contrast with the endodermal
origin of lung, liver and lymph nodes. The relationship of
SRF to the origin of the tissues combined with our finding
that high SRF in bone metastases is associated with
shorter survival supports the role of SRF as a marker of
docetaxel resistance, while the differential relationship
between nuclear SRF expressivity in bone and soft tissues
suggests SRF has a mechanistic role in bone metastasis.
Immuno-histochemical characterisation of a man’s
disease necessitates a biopsy specimen. Although this is
not the current standard of care for prostate cancer
patients, biopsy of new lesions in other malignancies has
led to treatment adjustments being carried out in as few
as one in seven patients [55]. Indeed in the context of
prostate cancer, despite its multifocal and multi-clonal
heterogeneity, most distant metastases from different
anatomic sites in the same patient share the majority of
genetic alterations [56–60]. As there is an increased risk
of bone fracture amongst this population, where Melton
et al. noted that 58% of men with castration resistant
prostate cancer sustain at least 1 pathologic fracture
[61], fixation of such fractures could represent one suit-
able time-point to obtain a biopsy for immuno-
histochemical analysis. Surgery has remained the domin-
ant modality by which solid cancers have been sampled
for such analyses, and some note that metastatic tissue
is often inaccessible and the purity and yield of biopsy
samples are low [62]. More recently though, work by the
Michigan Oncology Sequencing Project (MI-ONCO-
SEQ) [63], Hong et al. in Melbourne [64], and Van Allen
et al.[65] have successfully demonstrated that with im-
proved techniques and tools, the vehicle by which meta-
static tissue will be obtained for a model of personalised
medicine is image-guided percutaneous biopsy.
In order to investigate the functional role of SRF we
undertook SRF siRNA knockdown experiments and
demonstrated significant reversal in resistance to doce-
taxel in our PC-3 model of docetaxel resistant prostate
cancer. Previous studies by Prencipe et al. have demon-
strated that in a LNCaP model of castration resistance,
that SRF inhibition impacts upon cell death and prolifer-
ation [6]. As mentioned earlier, studies of the role of
SRF in prostate cancer are limited. However Taylor et al.
have demonstrated that SRF inhibition leads to integrin
activation and trafficking, and so reduces migration of
neutrophils in response to inflammation in both in-vivo
and in-vitro studies [66]. Knockout of SRF reduces
Enigma; a LIM domain protein which has been shown
to be highly expressed in bone metastases and may func-
tion as an oncoprotein [67]. Coupled together these
findings further suggest that SRF may play a role in pro-
gression of prostate cancer, and maybe an amenable
therapeutic target for manipulation at various disease
stages [6, 50].
There are limitations to the present study. Because
the functional work was performed in a single cell
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line it is difficult to make absolute assumptions about
the generalizability of the finding that resistance to
docetaxel can be overcome by inhibiting SRF in men
with advanced metastatic prostate cancer. Nevertheless, in
a personalised medicine approach where each man’s
disease is appropriately profiled, SRF inhibition may form
part of an appropriate therapeutic pathway.
Conclusions
The diagnosis and treatment of prostate cancer is based
on a series of clinical, radiological and pathological
criteria. Implicit in the adaptive and progressive nature
of the disease is that the biological characteristics and sen-
sitivity of metastases to hormonal and chemotherapies are
likely to change from that of the primary lesion; and so
further characterisation of metastatic lesions will be
required. Identification of treatment resistant prostate
cancer which is ultimately the most lethal form of the dis-
ease is a great clinical challenge. Stratification of prostate
cancer at an early stage could reduce the overtreatment of
many prostate cancers, identify those who are most likely
to progress sooner, and help predict response to hormone
and chemotherapies. Such markers to stratify the signifi-
cance of these prostate cancers at an early stage are
notably absent from the literature. Our results suggest that
SRF could be one such marker, and may also represent a
therapeutic target in the treatment of men afflicted with
advanced prostate cancer.
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